Anika Therapeutics (ANIK -0.1%) commences the U.S. commercial soft launch of TACTOSET, an injectable hyaluronic acid-enhanced bone repair therapy for bone voids and other bone defects caused by trauma or age-related degeneration.
The launch is the company’s first under its U.S.-based hybrid commercial model.
Management will be discussing the launch at its Analyst and Investor Day today.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.